Thursday, December 17, 2020

UI Pharmaceuticals, an Iowa-based provider of contract pharmaceutical product development and manufacturing services and a division of the University of Iowa College of Pharmacy, is very excited to announce that it has been chosen as a vendor for the National Institute of Allergy and Infectious Diseases (NIAID) Request for Proposal (RFP) No. 75N93019R00021, “CRO Support for Formulation, Development, and Manufacture of Clinical Dosage Forms; Task order title “Preclinical Services for HIV Therapeutics.” NIAID at the NIH (National Institutes of Health) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. Contracted organizations provide manufacturing, pharmacology, toxicology, regulatory, and clinical operations services to NIAID to assist with probe and assay development, lead selection and optimization, and Investigational New Drug studies. The goal of NIAID in selecting UI Pharmaceuticals as a vendor is to obtain contract research services to support the development, manufacturing, and stability studies of dosage forms of experimental therapeutics.  UI Pharmaceuticals works with the faculty to enable these types of projects.

In addition to working with government agencies, UI Pharmaceuticals has a wide range of clients, partners, and collaborators that include both the U.S. and international companies, from start-up organizations to mid-tier biotech companies.

About UI Pharmaceuticals:

UI Pharmaceuticals is the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States that produces both sterile and non-sterile dosage forms, we have been developing formulations, manufacturing products, and conducting analytical testing for almost 45 years.  UI Pharmaceuticals can support the manufacturing and testing of preclinical, clinical, and commercial products.